On March 31st, GlaxoSmithKline
announced that it would give poorer countries cheap access to cancer drugs. It was the latest initiative from a company that, under CEO, Andrew Witty, had been ready to ask some of the hard questions of the pharmaceutical industry business model. But it seems that some of the defenders of the status quo may have won, for Witty is to step down from the top job next year. So is it back to business as usual from now on?